| 摘要 |
Although adjuvant, or additional, therapy after surgery (e.g., adjuvant, or additional, hormonal therapy after breast cancer surgery) is performed to prevent postoperative recurrence of malignant tumors such as breast cancer, the incidence of disease recurrence still remains even if a representative drug, tamoxifen, commonly used is given. Thus, if it is possible to predict whether malignant tumors are reliably curable with tamoxifen or whether therapeutic drugs other than tamoxifen should be selected or not against such malignant tumors, it will greatly assist in the therapeutic guideline for preventing postoperative recurrence. There is a possibility that menin regulates the ER transcription activity in breast cancer cells. The expression of menin is remarkably responsible for the efficacy of estrogen antagonists (e.g., tamoxifen) having an inhibitory activity on estrogen binding to the ER. Techniques utilizing the present findings are provided. That is, provided is use of menin and menin expression gene as markers for probing the efficacy of therapeutic drugs (e.g., anti-cancer agents, antineoplastic agents) on tumor cells (e.g., breast cancer) or drug resistance markers for such therapeutic drugs, related reagents and methods for measurement/detection as well as systems utilizing them.
|
